Introduction
============

The ErbB family of proteins consists of four receptor tyrosine kinases: ErbB1/human epidermal growth factor receptor (HER)1/epidermal growth factor receptor (EGFR), ErbB2/HER2, ErbB3/HER3 and ErbB4/HER4 ([@b1-ijmm-43-03-1281]). The overexpression or overactivity of EGFR has been linked to a number of types of cancer, including lung cancer, colon cancer, glioblastoma, and head and neck squamous cell carcinoma ([@b2-ijmm-43-03-1281]--[@b5-ijmm-43-03-1281]).

A previous study demonstrated that a series of analogues of emodin, which is an anthraquinone derivative, exhibited potent antiproliferative activity in three HER2-overexpressing cell lines, FaDu, HSC3 and OECM1 ([@b6-ijmm-43-03-1281]). Following molecular docking simulation, the results revealed that not all of these compounds were able to dock into the binding site of the HER2 protein. However, a number of anthraquinone derivatives, including the emodin analogues of the previous study, docked into the binding site of the EGFR protein during a docking simulation, and the majority of these compounds exhibited similar docking poses within the EGFR kinase domain. EGFR and HER2 are members of the ErbB protein family, with the FaDu and OECM1 cell lines being EGFR^+^/HER2^+^ cell lines, and HSC3 being an EGFR^+^/EGR2^−^ cell line. It has been indicated that emodin preferentially suppresses the phosphorylation activities of HER-2/neu, compared with EGFR, but also that emodin is also able to suppress the EGF-induced tyrosine phosphorylation of EGFR at high concentrations ([@b7-ijmm-43-03-1281]). In addition, chrysophanic acid, which is a natural anthraquinone, has been demonstrated to exhibit antiproliferative activity by inhibiting the EGF-induced phosphorylation of EGFR and suppressing the activation of downstream signalling molecules ([@b8-ijmm-43-03-1281]). As the 38 compounds in the previous study had superior antiproliferative activity in the FaDu cell line than the other two cell lines, the present study aimed to determine whether these anthraquinone derivatives exhibit potent antiproliferative activity in EGFR-overexpressing cell lines rather than HER2-overexpressing cell lines by assessing the antiproliferative activity of the FaDu cell line.

In the present study, a number of quantitative structure-activity relationship (QSAR) models were applied in order to identify the association between the functional groups of anthraquinone derivatives and their antitumour functions. The docking simulation indicated the possible docking poses of anthraquinone derivatives in the EGFR kinase domain.

Materials and methods
=====================

Data collection
---------------

A total of 38 anthraquinone derivatives were collected as described previously ([Fig. 1](#f1-ijmm-43-03-1281){ref-type="fig"}; [Table I](#tI-ijmm-43-03-1281){ref-type="table"}) ([@b6-ijmm-43-03-1281]). All 38 compounds were drawn using ChemBioOffice 2010 v12.0 (<http://www.cambridgesoft.com/services/>), and each compound was prepared using the Prepare Ligand protocol in Discovery Studio v2.5 (DS2.5) (Accelrys Software, Inc., San Diego, CA, USA.) to modify its ionization to the physiological state.

As described previously ([@b6-ijmm-43-03-1281]), the efficacy of antitumour activity was determined using a modified MTT method, and the half maximal inhibitory concentration (IC~50~) value was calculated by linear regression analysis ([@b9-ijmm-43-03-1281]). The FaDu cells (3,000 cells/well) were seeded into 96-well plates with a vehicle (dimethyl sulfoxide) or various concentrations of 38 test compounds using the dose range of 0--100 *µ*M for 72 h at 37°C (5% CO~2~). The MTT (5 *µ*g/ml) was added after 70 h of incubation. Subsequently, 40% dimethylformamide and 20% sodium dodecyl sulphate in H~2~O was treated as a solubilisation buffer and added into the wells to dissolve the violet formazan precipitation overnight at 37°C. A microplate reader (Molecular Devices, LLC, Sunnyvale, CA, USA) was used to detect the absorbance at 570 nm, and the linear regression analysis was performed to calculate the IC~50~ value. The IC~50~ value of the 38 test compounds for FaDu cells was found to lie between 7.3 *µ*M (compound 17) and 2,285 *µ*M (compound 14).

The X-ray crystal structures of the wild-type and T790M/L858R (TMLR) mutant EGFR kinase domains were obtained from the Research Collaboratory for Structural Bioinformatics Protein Data Bank (PDB ID, 5CAV and 5CAS, respectively; <http://www.rcsb.org>) ([@b10-ijmm-43-03-1281]) for use in the molecular docking simulation. The protein preparation of each EGFR kinase domain was performed using the Prepare Protein protocol in DS2.5 to remove water atoms from the crystals, insert missing atoms in incomplete residues, protonate the structure of EGFR kinase domain using the Chemistry at HARvard Macromolecular Mechanics (CHARMM) force field ([@b11-ijmm-43-03-1281]), and optimise the side-chain conformation of residues with inserted atoms. The binding site of each EGFR kinase domain was defined as the volume of co-crystallised inhibitor present in the initial crystal structure.

2D-QSAR modeling
----------------

Multiple linear regression (MLR) and a support vector machine (SVM) were employed to construct the 2D-QSAR models using MATLAB R2010b (<https://www.mathworks.com/products/matlab.html>) and LibSVM v.2.91 (<https://www.csie.ntu.edu.tw/~cjlin/libsvm/>) ([@b12-ijmm-43-03-1281]), respectively. All 38 compounds were divided randomly into training and test sets (28 and 10 compounds, respectively), and their IC~50~ values were determined as *p*IC~50~ values (−logIC~50~). The genetic function approximation ([@b13-ijmm-43-03-1281]) protocol in DS2.5 was employed to identify the suitable molecular descriptors for the prediction models.

Docking simulation
------------------

The docking poses for each compound were calculated using the LigandFit protocol ([@b14-ijmm-43-03-1281]) in DS2.5 using a shape filter and Monte-Carlo ligand conformation generation, followed by optional minimisation with the CHARMM force field ([@b11-ijmm-43-03-1281]). Similar docking poses of each compound were filtered using the leader algorithm ([@b15-ijmm-43-03-1281]). The optimal docking pose of each compound was determined according to its interactions with the EGFR kinase domains and three scoring functions, -PLP1, -PLP2 and -PMF ([@b16-ijmm-43-03-1281]--[@b18-ijmm-43-03-1281]), which were evaluated by summing two types of pairwise interaction, hydrogen bonding (H-bonding) and steric interactions.

Comparative force field analysis (CoMFA) and comparative similarity indices analysis (CoMSIA)
---------------------------------------------------------------------------------------------

CoMFA ([@b19-ijmm-43-03-1281]) and CoMSIA ([@b20-ijmm-43-03-1281]) were used on the 28 compounds in the training set to construct 3D-QSAR models using SYBYL-X v1.1 (<http://www.tripos.com>). CoMFA, with the distance-dependent dielectric method, was performed to evaluate the steric and electrostatic field descriptors using Lennard-Jones and Coulombic potential energies, respectively. CoMSIA may produce more stable models than CoMFA, as it was performed with a Gaussian function based on distance in order to evaluate five physicochemical parameters (steric, electrostatic and hydrophobic properties, and H-bond donor and acceptor). The partial least-squares regression method was used to analyse the 3D-QSAR models.

Results
=======

2D-QSAR modelling
-----------------

The chemical scaffolds of the anthraquinone derivatives are shown in [Fig. 1](#f1-ijmm-43-03-1281){ref-type="fig"}, and their *p*IC~50~ values are listed in [Table I](#tI-ijmm-43-03-1281){ref-type="table"}. The seven representative descriptors for building 2D-QSAR models, identified using genetic function approximation, were \'ES_Count_ssO\', \'Num_H\_Donors\', \'Jurs_FPSA_3′, \'Jurs_RNCS\', \'Jurs_RPCS\', \'Shadow_XYfrac\' and \'Shadow_XZ\'.

The \'ES_Count_ssO\' descriptor is an electrotopological state key ([@b21-ijmm-43-03-1281],[@b22-ijmm-43-03-1281]) and represents the count of oxygen atoms with two single bonds. For the \'Num_H\_Donors\' descriptor, H-bond donors are defined as heteroatoms (O, N, S and P) with ≥1 attached H atom. The \'Jurs\' descriptors ([@b23-ijmm-43-03-1281]) combine shape and electronic information to characterise molecules, by mapping atomic partial charges on the solvent-accessible surface areas of individual atoms. The \'Jurs_FPSA_3′ descriptor covers the fractional charged partial surface areas, which are obtained by dividing the total charge-weighted positive surface area by the total molecular solvent-accessible surface area. The \'Jurs_RNCS\' and \'Jurs_RPCS\' descriptors report the relative negatively and positively charged surface areas, respectively. The \'Shadow_XYfrac\' and \'Shadow_XZ\' descriptors are shadow indices ([@b24-ijmm-43-03-1281]), which calculate the area of the molecular shadow in the xy- and xz-plane, respectively.

An MLR model was established with the training set of 28 compounds, using the aforementioned seven descriptors selected by genetic function approximation, and the test set of 10 compounds was used to evaluate the final MLR model. The equation of the MLR model was as follows: *p*IC~50~=−5.513 − 0.235 × \'ES_Count_ssO\' − 0.895 × \'Num_H\_ Donors\' + 100.724 × \'Jurs_FPSA_3′ − 0.078 × \'Jurs\_ RNCS\' − 0.124 × \'Jurs_RPCS\' + 6.406 × \'Shadow\_ XYfrac\' + 0.058 × \'Shadow_XZ\'.

A non-linear SVM model was established with the same training set and descriptors as the MLR model. The predicted *p*IC~50~ values obtained by the MLR and SVM models are listed in [Table II](#tII-ijmm-43-03-1281){ref-type="table"}, and the correlation between the predicted and experimental *p*IC~50~ values for the two models are shown in [Fig. 2A and B](#f2-ijmm-43-03-1281){ref-type="fig"}.

Docking simulation
------------------

The binding sites of the wild-type (PDB ID, 5CAV) and TMLR mutant (PDB ID, 5CAS) EGFR kinase domains were defined as the volume of co-crystallised inhibitors present in the initial crystal structures. A docking simulation was performed to validate the accuracy of the LigandFit protocol by redocking the co-crystallised EGFR inhibitor into the binding site of each EGFR kinase domain. The values of the root-mean-square deviation between the crystallised structure and the docking pose of the inhibitor were 0.4706 and 0.4322 for the wild-type and TMLR mutant, respectively.

The results of the docking simulations for all 38 anthraquinone derivatives in the binding site of each EGFR kinase domain are listed in [Table III](#tIII-ijmm-43-03-1281){ref-type="table"}. The docking poses of three high-affinity compounds, 15, 20 and 35, in each EGFR kinase domain, are shown in [Fig. 3A--F](#f3-ijmm-43-03-1281){ref-type="fig"}.

CoMFA and CoMSIA
----------------

In order to identify the association between the functional groups of the compounds and their bioactivities, the CoMFA and CoMSIA models were established using the wild-type EGFR kinase domain (PDB ID, 5CAV). Therefore, the associations between the bioactivities and five physicochemical parameters (steric, electrostatic and hydrophobic properties, and H-bond donor and acceptor) were analysed.

For alignment of the 38 compounds, all were superimposed according to their docking poses. The predicted *p*IC~50~ values obtained by the CoMFA model using three components and the CoMSIA model using two components are listed in [Table IV](#tIV-ijmm-43-03-1281){ref-type="table"}, and the correlations between the predicted and experimental *p*IC~50~ values of the CoMFA and CoMSIA models are shown in [Fig. 4A and B](#f4-ijmm-43-03-1281){ref-type="fig"}. The squared correlation coefficients (R^2^) values of the training set were 0.7078 and 0.7069 for the CoMFA and CoMSIA models, respectively. The results of the CoMFA and CoMSIA models with high-affinity compound 20 are graphically represented by field contribution maps in [Fig. 5](#f5-ijmm-43-03-1281){ref-type="fig"}.

In the CoMFA model ([Fig. 5A](#f5-ijmm-43-03-1281){ref-type="fig"}), the proportions of steric and electrostatic fields were 100 and 0%, respectively. The favoured and disfavoured cut-off energies were set at 80 and 20%, respectively, for the steric field contributions.

In the CoMSIA model ([Fig. 5B](#f5-ijmm-43-03-1281){ref-type="fig"}), the fractions of the hydrophobicity, H-bond donor and H-bond acceptor fields were 36.0, 43.5 and 20.5%, respectively. The favoured and disfavoured cut-off energies were set at 80 and 20%, respectively, for the hydrophobic contributions. For the field contributions of the H-bond donor properties ([Fig. 5C](#f5-ijmm-43-03-1281){ref-type="fig"}), the favoured and disfavoured cut-off energies were set at 80 and 20%, respectively. For the field contributions of the H-bond acceptor properties ([Fig. 5D](#f5-ijmm-43-03-1281){ref-type="fig"}), the favoured and disfavoured cut-off energies were set at 85 and 15%, respectively.

Discussion
==========

2D-QSAR modelling
-----------------

The majority of the predicted *p*IC~50~ values are within the 95% prediction bands, and the R^2^ values for the training set were \>0.7, at 0.7723 and 0.8304 in the MLR and SVM models, respectively. The two models predicted reasonable bioactivities for the anthraquinone derivatives. The results indicate that the seven representative descriptors of anthraquinone derivatives are associated with their antitumour function.

Docking simulation
------------------

As shown in [Fig. 3](#f3-ijmm-43-03-1281){ref-type="fig"}, the compounds formed π-cation interactions with the Lys745 residue and an H-bond with Thr790. As the mutation of T790M reduces the activity of EFGR inhibitors through inhibition of part of their interaction, in the resistant T790M mutant EGFR, π-cation interactions or H-bonds with residue Lys745 were present, but the H-bond between the compounds and Met790 was not. Instead, all three of the high-affinity compounds formed an H-bond with Thr854.

CoMFA and CoMSIA
----------------

As shown in [Fig. 5A](#f5-ijmm-43-03-1281){ref-type="fig"}, part of the favoured steric field was observed close to the R^3^ and R^4^ moieties and some disfavoured steric field for the R^6^ moiety was observed towards Thr790 and Thr854. As shown in [Fig. 5B](#f5-ijmm-43-03-1281){ref-type="fig"}, a favoured hydrophobic field for the R^6^ moiety was observed towards Thr854, with some disfavoured hydrophobic field close to the R^3^ moieties. As shown in [Fig. 5C](#f5-ijmm-43-03-1281){ref-type="fig"} and [5D](#f5-ijmm-43-03-1281){ref-type="fig"}, the introduction of an H-bond donor and acceptor in the region may improve the activity.

In the present study, the MLR and SVM models indicated seven representative molecular descriptors of anthraquinone derivatives associated with their antitumour activities. The docking simulation indicated the possible docking poses of anthraquinone derivatives binding in the wild-type and resistant T790M mutant EGFR kinase domain. These compounds formed π-cation interactions with Lys745 and H-bonds with Thr790, and in the mutant EGFR kinase domain, H-bonds were formed with Thr854 instead of Met790. The CoMFA and CoMSIA models indicated the favoured and disfavoured fields for four physicochemical properties (steric, hydrophobic, H-bond donor, and H-bond acceptor), which may further improve the antitumour functions. The favoured steric fields and disfavoured hydrophobic fields were revealed close to the R^3^ moieties. The disfavoured steric fields and favoured hydrophobic fields for the R^6^ moiety were observed towards Thr854. As the compounds of the training set used in QSAR models have similar main scaffolds, those compounds with different main scaffolds may not fit these models. In addition, the results of a docking simulation can indicate that these compounds have suitable docking poses in the EGFR kinase domain, but they cannot be used to evaluate the antiproliferative activity of compounds. However, the results suggested the benefit of further investigations being performed to develop lead compounds with improved anticancer bioactivity. In future experiments, a series of analogues may be synthesised by adding larger hydrophilic substitutes in the R^3^ or R^4^ moieties and small hydrophobic substitutes in the R^6^ moiety in order to determine suitable anthraquinone derivatives with superior anticancer bioactivity against EGFR-overexpressing cell lines.
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###### 

*p*IC~50~ values of anthraquinone derivatives in the FaDu cell line.

  Compound                                                  R^1^     R^2^      R^3^       R^4^       R^5^     R^6^     *p*IC~50~
  --------------------------------------------------------- -------- --------- ---------- ---------- -------- -------- -----------
  Emodin                                                    −OH      −OH       −OH        −H         −CH~3~   −H       4.33
  Physicon[a](#tfn1-ijmm-43-03-1281){ref-type="table-fn"}   −OMe     −OH       −OH        −H         −CH~3~   −H       3.46
  3                                                         −OCOMe   −OCOMe    −OCOMe     −H         −COOH    −H       3.93
  4                                                         −OH      −OH       −OH        −H         −COOH    −H       3.96
  5                                                         −OCOMe   −OCOMe    −OCOMe     −H         −CH~3~   −H       4.48
  6                                                         −OCOEt   −OCOEt    −OCOEt     −H         −CH~3~   −H       4.45
  7[a](#tfn1-ijmm-43-03-1281){ref-type="table-fn"}          −OCOPr   −OCOPr    −OCOPr     −H         −CH~3~   −H       4.34
  8                                                         −OCOBu   −OCOBu    −OCOBu     −H         −CH~3~   −H       4.37
  9                                                         −OMe     −OMe      −OMe       −H         −CH~3~   −H       4.41
  10                                                        −H       −H        −NH~2~     −NH~2~     −H       −H       3.63
  11                                                        −H       −H        −H         −COOH      −H       −H       3.79
  12[a](#tfn1-ijmm-43-03-1281){ref-type="table-fn"}         −H       −H        −H         −CH~3~     −H       −H       4.06
  13[a](#tfn1-ijmm-43-03-1281){ref-type="table-fn"}         −H       −H        −H         −SO~3~Na   −H       −H       3.51
  14                                                        −H       −H        −SO~3~Na   −H         −H       −H       2.64
  15                                                        −H       −H        −OH        −H         −H       −OH      4.83
  16[a](#tfn1-ijmm-43-03-1281){ref-type="table-fn"}         −H       −H        −OH        −OH        −H       −OH      4.39
  17[a](#tfn1-ijmm-43-03-1281){ref-type="table-fn"}         --       --        --         --         --       --       5.14
  18                                                        −H       −H        −NHMe      −H         −H       −NHMe    3.04
  19                                                        −H       −SO~3~K   −SO~3~K    −H         −H       −H       3.74
  20[a](#tfn1-ijmm-43-03-1281){ref-type="table-fn"}         −H       −OH       −OH        −H         −H       −H       4.83
  21                                                        −H       −OH       −H         −H         −H       −OH      4.42
  22                                                        −OH      −H        −H         −OH−       −H       −H       3.91
  23                                                        −H       −H        −OH        −OH        −H       −H       3.77
  24[a](#tfn1-ijmm-43-03-1281){ref-type="table-fn"}         −NH~2~   −H        −H         −NH~2~     −H       −H       4.38
  25                                                        −H       −H        −H         −OH        −NH~2~   −H       4.49
  26                                                        −H       −H        −H         −NH~2~     −H       −H       4.44
  27                                                        −H       −H        −H         −Et        −H       −H       4.01
  28[a](#tfn1-ijmm-43-03-1281){ref-type="table-fn"}         −H       −H        −NH~2~     −H         −H       −NH~2~   3.81
  29                                                        −H       −NH~2~    −H         −H         −H       −NH~2~   4.95
  30                                                        −H       −H        −NHMe      −H         −H       −H       4.23
  31                                                        −H       −H        −NH~2~     −CH~3~     −H       −H       4.25
  32                                                        −H       −H        −NH~2~     −H         −H       −H       4.40
  33                                                        −H       −H        −OH        −H         −H       −H       4.40
  34                                                        −H       −H        −H         −OH        −H       −H       3.16
  35                                                        −H       −OCOMe    −OCOMe     −H         −H       −H       4.65
  36                                                        −H       −OCOEt    −OCOEt     −H         −H       −H       4.17
  37[a](#tfn1-ijmm-43-03-1281){ref-type="table-fn"}         −H       −OCOPr    −OCOPr     −H         −H       −H       4.48
  38                                                        −H       −OCOBu    −OCOBu     −H         −H       −H       4.40

Test set. IC~50~, half maximal inhibitory concentration; *p*IC~50~, −log(IC~50~).

###### 

Experimental and predicted *p*IC~50~ values obtained by the MLR and SVM models.

  Compound                                                  Experimental *p*IC~50~   MLR    SVM            
  --------------------------------------------------------- ------------------------ ------ ------- ------ -------
  Emodin                                                    4.33                     4.33   0.00    4.21   −0.12
  Physicon[a](#tfn2-ijmm-43-03-1281){ref-type="table-fn"}   3.46                     4.45   0.99    4.00   0.54
  3                                                         3.93                     4.19   0.26    4.05   0.12
  4                                                         3.96                     3.88   −0.08   3.84   −0.12
  5                                                         4.48                     4.27   −0.21   4.35   −0.13
  6                                                         4.45                     3.99   −0.46   4.33   −0.12
  7[a](#tfn2-ijmm-43-03-1281){ref-type="table-fn"}          4.34                     4.29   −0.05   4.41   0.07
  8                                                         4.37                     4.53   0.16    4.46   0.09
  9                                                         4.41                     4.57   0.16    4.54   0.13
  10                                                        3.63                     4.25   0.62    3.93   0.30
  11                                                        3.79                     3.49   −0.30   3.66   −0.13
  12[a](#tfn2-ijmm-43-03-1281){ref-type="table-fn"}         4.06                     3.76   −0.30   3.97   −0.09
  13[a](#tfn2-ijmm-43-03-1281){ref-type="table-fn"}         3.51                     3.18   −0.33   2.84   −0.67
  14                                                        2.64                     2.70   0.06    2.77   0.13
  15                                                        4.83                     4.68   −0.15   4.71   −0.12
  16[a](#tfn2-ijmm-43-03-1281){ref-type="table-fn"}         4.39                     4.20   −0.19   4.09   −0.30
  17[a](#tfn2-ijmm-43-03-1281){ref-type="table-fn"}         5.14                     4.86   −0.28   4.63   −0.51
  18                                                        3.04                     3.14   0.10    3.16   0.12
  19                                                        3.74                     3.77   0.03    3.87   0.13
  20[a](#tfn2-ijmm-43-03-1281){ref-type="table-fn"}         4.83                     4.81   −0.02   4.81   −0.02
  21                                                        4.42                     4.67   0.25    4.66   0.24
  22                                                        3.91                     3.90   −0.01   3.87   −0.04
  23                                                        3.77                     3.87   0.10    3.90   0.13
  24[a](#tfn2-ijmm-43-03-1281){ref-type="table-fn"}         4.38                     4.43   0.05    3.91   −0.47
  25                                                        4.49                     4.12   −0.37   4.16   −0.33
  26                                                        4.44                     4.39   −0.05   4.31   −0.13
  27                                                        4.01                     3.96   −0.05   3.93   −0.08
  28[a](#tfn2-ijmm-43-03-1281){ref-type="table-fn"}         3.81                     4.23   0.42    4.07   0.26
  29                                                        4.95                     4.36   −0.59   4.15   −0.80
  30                                                        4.23                     4.31   0.08    4.27   0.04
  31                                                        4.25                     4.25   0.00    4.12   −0.13
  32                                                        4.40                     4.42   0.02    4.46   0.06
  33                                                        4.40                     4.25   −0.15   4.28   −0.12
  34                                                        3.16                     3.62   0.46    3.55   0.39
  35                                                        4.65                     4.72   0.07    4.56   −0.09
  36                                                        4.17                     4.17   0.00    4.30   0.13
  37[a](#tfn2-ijmm-43-03-1281){ref-type="table-fn"}         4.48                     4.29   −0.19   4.31   −0.17
  38                                                        4.40                     4.47   0.07    4.28   −0.12

Test set. MLR, multiple linear regression; SVM, support vector machine; IC~50~, half maximal inhibitory concentration; *p*IC~50~, −log(IC~50~).

###### 

Scoring functions of each complex obtained by docking simulation.

  Compound                                                  *p*IC~50~   5CAV     5CAS                              
  --------------------------------------------------------- ----------- -------- -------- -------- ------- ------- --------
  Emodin                                                    4.33        64.62    71.20    91.21    73.07   76.99   93.72
  Physicon[a](#tfn3-ijmm-43-03-1281){ref-type="table-fn"}   3.46        44.51    43.67    96.99    43.12   41.73   62.42
  3                                                         3.93        65.20    59.92    111.74   83.79   76.72   81.25
  4                                                         3.96        79.81    86.22    88.59    87.77   89.76   88.21
  5                                                         4.48        62.67    55.15    122.56   79.83   71.08   126.61
  6                                                         4.45        72.30    61.25    99.36    61.80   53.20   127.27
  7[a](#tfn3-ijmm-43-03-1281){ref-type="table-fn"}          4.34        102.78   101.73   86.88    75.07   70.05   150.17
  8                                                         4.37        103.66   94.66    101.74   95.34   90.63   109.19
  9                                                         4.41        56.21    51.77    104.36   55.03   54.33   105.17
  10                                                        3.63        53.83    52.39    76.19    60.32   63.13   76.37
  11                                                        3.79        64.02    65.84    51.38    61.56   54.57   79.38
  12[a](#tfn3-ijmm-43-03-1281){ref-type="table-fn"}         4.06        53.95    54.22    57.21    57.18   57.87   80.13
  13[a](#tfn3-ijmm-43-03-1281){ref-type="table-fn"}         3.51        67.65    72.88    42.90    54.8    49.32   76.73
  14                                                        2.64        59.11    56.33    68.86    58.39   60.44   83.99
  15                                                        4.83        47.60    48.20    89.25    50.42   53.99   101.97
  16[a](#tfn3-ijmm-43-03-1281){ref-type="table-fn"}         4.39        49.73    53.42    103.26   62.46   69.88   102.27
  17[a](#tfn3-ijmm-43-03-1281){ref-type="table-fn"}         5.14        45.57    48.18    87.04    55.28   58.20   95.57
  18                                                        3.04        64.69    64.20    58.02    65.39   63.78   86.34
  19                                                        3.74        54.02    55.81    91.70    60.02   63.80   84.75
  20[a](#tfn3-ijmm-43-03-1281){ref-type="table-fn"}         4.83        49.31    49.87    83.80    61.24   62.95   90.19
  21                                                        4.42        47.57    49.08    89.96    59.00   60.92   87.61
  22                                                        3.91        55.02    57.83    94.92    56.47   56.86   84.56
  23                                                        3.77        50.46    54.35    99.94    60.46   67.85   97.32
  24[a](#tfn3-ijmm-43-03-1281){ref-type="table-fn"}         4.38        56.09    54.18    89.29    55.40   47.37   75.34
  25                                                        4.49        58.32    56.39    68.49    58.22   62.31   92.49
  26                                                        4.44        54.69    54.25    46.94    56.09   55.54   76.29
  27                                                        4.01        58.49    58.55    62.80    61.69   58.24   50.50
  28[a](#tfn3-ijmm-43-03-1281){ref-type="table-fn"}         3.81        53.69    53.67    81.66    62.51   64.48   79.19
  29                                                        4.95        55.19    55.90    82.85    62.27   63.53   85.81
  30                                                        4.23        55.05    55.05    62.42    56.17   56.77   79.84
  31                                                        4.25        55.41    55.12    56.78    60.56   57.02   44.52
  32                                                        4.40        51.96    52.18    83.14    59.91   61.83   77.87
  33                                                        4.40        47.67    46.35    69.79    53.19   54.67   79.28
  34                                                        3.16        48.39    50.31    95.00    55.33   58.62   82.15
  35                                                        4.65        58.96    56.96    110.18   65.63   66.48   101.84
  36                                                        4.17        65.34    62.50    118.53   74.46   72.09   108.60
  37[a](#tfn3-ijmm-43-03-1281){ref-type="table-fn"}         4.48        63.10    60.99    130.19   80.10   77.80   122.05
  38                                                        4.40        68.72    68.51    129.06   81.43   79.45   127.00

Test set. IC~50~, half maximal inhibitory concentration; *p*IC~50~, −log(IC~50~).

###### 

Experimental and predicted *p*IC~50~ values obtained by the CoMFA and CoMSIA models for 28 compounds in the training set and 10 compounds in the test set.

  Compound                                                  Experimental *p*IC~50~   CoMFA   CoMSIA          
  --------------------------------------------------------- ------------------------ ------- -------- ------ -------
  Emodin                                                    4.33                     3.83    −0.50    3.83   −0.21
  Physicon[a](#tfn4-ijmm-43-03-1281){ref-type="table-fn"}   3.46                     4.22    0.76     4.22   0.57
  3                                                         3.93                     3.91    −0.02    3.91   0.19
  4                                                         3.96                     3.81    −0.15    3.81   0.17
  5                                                         4.48                     4.49    0.01     4.49   0.23
  6                                                         4.45                     4.70    0.25     4.70   0.03
  7[a](#tfn4-ijmm-43-03-1281){ref-type="table-fn"}          4.34                     3.33    −1.01    3.33   −0.11
  8                                                         4.37                     4.31    −0.06    4.31   0.11
  9                                                         4.41                     4.29    −0.12    4.29   −0.30
  10                                                        3.63                     4.20    0.57     4.20   −0.12
  11                                                        3.79                     3.72    −0.07    3.72   0.07
  12[a](#tfn4-ijmm-43-03-1281){ref-type="table-fn"}         4.06                     4.08    0.02     4.08   0.11
  13[a](#tfn4-ijmm-43-03-1281){ref-type="table-fn"}         3.51                     4.41    0.90     4.41   0.35
  14                                                        2.64                     3.37    0.73     3.37   0.58
  15                                                        4.83                     4.36    −0.47    4.36   −0.74
  16[a](#tfn4-ijmm-43-03-1281){ref-type="table-fn"}         4.39                     3.84    −0.55    3.84   −0.46
  17[a](#tfn4-ijmm-43-03-1281){ref-type="table-fn"}         5.14                     3.57    −1.57    3.57   −0.84
  18                                                        3.04                     2.90    −0.14    2.90   0.13
  19                                                        3.74                     3.90    0.16     3.90   −0.03
  20[a](#tfn4-ijmm-43-03-1281){ref-type="table-fn"}         4.83                     4.52    −0.31    4.52   −0.62
  21                                                        4.42                     4.36    −0.06    4.36   0.01
  22                                                        3.91                     3.67    −0.24    3.67   0.13
  23                                                        3.77                     3.69    −0.08    3.69   0.03
  24[a](#tfn4-ijmm-43-03-1281){ref-type="table-fn"}         4.38                     4.12    −0.26    4.12   −0.77
  25                                                        4.49                     4.40    −0.09    4.40   −0.62
  26                                                        4.44                     4.25    −0.19    4.25   −0.05
  27                                                        4.01                     3.74    −0.27    3.74   0.17
  28[a](#tfn4-ijmm-43-03-1281){ref-type="table-fn"}         3.81                     4.34    0.53     4.34   0.65
  29                                                        4.95                     4.94    −0.01    4.94   0.21
  30                                                        4.23                     4.25    0.02     4.25   −0.01
  31                                                        4.25                     4.23    −0.02    4.23   0.13
  32                                                        4.40                     4.62    0.22     4.62   0.11
  33                                                        4.40                     4.15    −0.25    4.15   −0.56
  34                                                        3.16                     3.72    0.56     3.72   0.35
  35                                                        4.65                     4.52    −0.13    4.52   −0.23
  36                                                        4.17                     4.36    0.19     4.36   0.17
  37[a](#tfn4-ijmm-43-03-1281){ref-type="table-fn"}         4.48                     4.25    −0.23    4.25   −0.21
  38                                                        4.40                     4.60    0.20     4.60   0.06

Test set. CoMFA, comparative force field analysis; CoMSIA, comparative similarity indices analysis; IC~50~, half maximal inhibitory concentration; *p*IC~50~, −log(IC~50~).
